Overview

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This research study is studying a combination of study drugs as a possible treatment for relapsed and refractory Multiple Myeloma. The interventions involved in this study are elotuzumab, pomalidomide, bortezomib, dexamethasone.

Phase:

Phase 2

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborators:

Bristol-Myers Squibb
Celgene
Multiple Myeloma Research Consortium

Treatments:

BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Elotuzumab
Pomalidomide
Thalidomide